Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Micafungin Prophylaxis in ICU
NCT00048750Phase 3Terminated
- Sponsor
- Astellas Pharma
- Start
- Jan 2003
- Primary completion
- Jun 2003
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial in invasive fungal infection (IFI) comparing Micafungin with Placebo (2 arms). Primary endpoint: Incidence of proven or probable invasive fungal infection. Started Jan 2003; status: terminated.
02
Drugs
micafungin
03
Conditions
invasive fungal infection (IFI)
Beyond the preview
Go deeper on NCT00048750.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00048750.